Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Efonidipine

Introduction

Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel.

It has also been studied in atherosclerosis[1] and acute renal failure.[2]

References

  1. ↑ Toyoda K, Kitahara M, Yamashita T; et al. (1994). “[Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits]”. Nippon Yakurigaku Zasshi (in Japanese). 103 (5): 231–9. PMID 8188119. Unknown parameter |month= ignored (help)
  2. ↑ Shudo C, Masuda Y, Sugita H, Tanaka S, Tomita K (1994). “Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats”. Gen. Pharmacol. 25 (7): 1451–8. PMID 7896060. Unknown parameter |month= ignored (help)


Template:Calcium channel blockers

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]